Ambient clinical AI developer Suki lands $90M, adding Healthier, Crosslink and Hercules

All existing institutional backers — Venrock, Flare Capital Partners, Hedosophia, Philips Ventures and Zoom Ventures — also participated in the financing, which Suki says will accelerate growth and expand its healthcare AI capabilities.

Suki, a Redwood City company that bills itself as a leader in Ambient Clinical Intelligence (ACI), has secured $90M in financing as part of its Series E, according to the company's announcement.

The round brings three new investors onto the cap table: Healthier Capital, Crosslink Capital and Hercules Capital. Every existing institutional investor also participated, including Venrock, Flare Capital Partners, Hedosophia, Philips Ventures and Zoom Ventures. The announcement did not name a single lead investor for the round, and it described the $90M as financing "as part of" the Series E rather than as the full size of that round.

On use of proceeds, the company was direct: the money is intended to accelerate growth and expand its healthcare AI capabilities. Suki positioned the raise squarely around its ACI franchise, the clinical-intelligence category in which it claims leadership — a framing that places the company's ambitions in healthcare AI rather than in general-purpose software.

The investor list is notable for its mix. Alongside traditional venture firms such as Venrock, Flare Capital Partners and Crosslink Capital, the round carries participation from corporate and strategic investors in Philips Ventures and Zoom Ventures, both of which re-upped rather than entering fresh. Healthier Capital and Hercules Capital are new additions to that group.

The announcement disclosed no valuation, no revenue figures and no headcount, and it did not break out how much of the $90M came from new versus returning investors. It also did not specify a timeline for deployment of the capital or which product lines would absorb the spend first.

What it did make clear is that Suki is staying the course on its stated specialization. In a funding environment where healthcare AI companies are being asked to show a defensible wedge, the company's message is that the wedge is ambient clinical intelligence — and that a roster of existing backers returning in force is the evidence it wants the market to weigh. Suki did not provide further comment beyond the financing announcement.